208 results about "Vaccine strain" patented technology

The invention discloses a virulence-attenuated bovine nodular skin disease virus LSDV-75 and application thereof, and belongs to the technical field of attenuated strains. The invention aims to provide a bovine nodular skin disease virus vaccine strain which is sufficient in attenuation and good in immune effect. The invention provides a virulence-attenuated bovine nodular skin disease virus strain, which is named as sheep pox virus LSDV-75, has the preservation number of CCTCC NO: V2024114, and is preserved in the China Center for Type Culture Collection on December 2, 2024. The vaccine strain provided by the invention can be used as a vaccine candidate strain for safely and effectively preventing and controlling bovine nodular dermatosis.

The invention discloses a virulence-attenuated bovine nodular skin disease virus LSDV DQ and application thereof, and belongs to the technical field of attenuated strains. The invention aims to provide a bovine nodular skin disease virus vaccine strain which is sufficient in attenuation and good in immune effect. The invention provides a virulence-attenuated bovine nodular skin disease virus strain, which is named as sheep pox virus LSDV-DQ, has the preservation number of CCTCC NO: V2024113, and is preserved in the China Center for Type Culture Collection on December 2, 2024. The vaccine strain provided by the invention can be used as a vaccine candidate strain for safely and effectively preventing and controlling bovine nodular dermatosis.

The invention relates to the technical field of biology, and aims to provide a monoclonal antibody 7A12 for identifying gene type 2 swine fever as well as a preparation method and an application method of the monoclonal antibody 7A12. The monoclonal antibody comprises Ig structural domains VH CDR1, VH CDR2 and VH CDR3 of a heavy chain of the antibody, and Ig structural domains VL CDR1, VL CDR2 and VL CDR3 of a light chain of the antibody, wherein the amino acid sequences of the VH CDR1, the VH CDR2 and the VH CDR3 are respectively as shown in SEQ ID NO: 1 to SEQ ID NO: 3; the amino acid sequences of the VL CDR1, the VL CDR2 and the VL CDR3 are respectively as shown in SEQ ID NO: 4 to SEQ ID NO: 6. The antibody provided by the invention has the advantages of high titer, strong specificity, high affinity and the like; the kit has the advantages of high sensitivity and strong specificity, has no cross reaction with the type 1 swine fever vaccine strain, and can identify and diagnose swine fever gene type 2 wild strain infection and vaccine immunity in serology; the method can be further used for establishing a blocking ELISA kit for identifying the gene type 2 hog cholera, and can effectively diagnose and purify the gene type 2 hog cholera virus.

The invention discloses a toxoplasma gondii attenuated vaccine strain RH delta rop67 as well as a construction method and application thereof, and belongs to the technical field of parasitic disease prevention and control and biological product preparation. The attenuated vaccine strain is constructed by performing targeted knockout on the ROP67 gene in a toxoplasma gondii strain RH delta ku80 through a CRISPR / Cas9 mediated gene editing technology. Compared with a wild type strain, the attenuated vaccine strain shows remarkable attenuation characteristic and good immunogenicity. A test result shows that the attenuated vaccine strain can induce a host to generate specific immune response mainly based on cellular immunity, maintains a protection effect on toxoplasma gondii infection in a relatively long immune period, and has a protection effect on tachyzoite infection and a chronic infection stage of toxoplasma gondii strains with different virulence; the survival ability of a host to tachyzoite infection can be improved, and the formation level of cysts in tissues is reduced. The invention provides a technical scheme with long-term immune potential for research and development of toxoplasma gondii attenuated vaccines.

The invention discloses a recombinant HVT for co-expressing an H9 subtype AIV HA gene, an IBV S gene and an IBDV VP2 gene and application of the recombinant HVT, and belongs to the technical field of medicine or veterinary medicine. The recombinant HVT is a recombinant HVT vaccine strain H30201 for co-expressing the H9 subtype AIV HA gene, the IBV S gene and the IBDV VP2 gene, which is obtained by inserting an expression cassette containing the H9 subtype AIV HA gene and the QX type IBV S gene between 95322-95323 nucleotides of an HVT FC126 strain and inserting an expression cassette containing the IBDV classic virulent strain VP2 gene between 112071-112088 nucleotides of an HVT genome at the same time through virus rescue. The invention also provides application of the recombinant HVT vaccine strain in preparation of vaccines for H9 subtype avian influenza, infectious bronchitis and infectious bursal disease.

The invention belongs to the technical field of gene engineering, and particularly discloses a construction method and application of a toxoplasma gondii gene knockout vaccine strain, a TGGT1202920 gene of toxoplasma gondii is directly knocked out through a gene editing technology to obtain a delta TGGT1202920 strain, and the strain has the characteristics that the strain can be normally cultured in vitro and is almost non-toxic in vivo; after animals are immunized with delta TGGT1202920 strains, good immune protection can be generated, infection of wild type toxoplasma gondii can be resisted, and the strain can be used for preparing toxoplasmosis resistant vaccines to prevent toxoplasma gondii infection.

The invention provides a construction method and application of a recombinant herpesvirus turkey for co-expressing an NDV (Newcastle Disease Virus) F gene and an H9 subtype AIV (Avian Influenza Virus) HA gene, and belongs to the field of genetic engineering vaccines. The recombinant clone technology is utilized, an expression framework containing a Newcastle disease virus gene VII type strain F gene and an H9 subtype avian influenza virus HA gene is inserted between 95322-95323 nucleotides or between 112071-112088 nucleotides of a turkey herpesvirus FC126 strain, and the recombinant clone with the F gene and HA gene expression framework inserted into a turkey herpesvirus genome is constructed and obtained. Recombinant turkey herpesvirus vaccine strains H20901 and H20902 for co-expressing the Newcastle disease virus F gene and the H9 subtype avian influenza virus HA gene are rescued and obtained by the recombinant turkey herpesvirus vaccine strain H20901 and H20902. The vaccine prepared from the recombinant turkey herpesvirus provided by the invention can provide dual protection for the Newcastle disease virus and the avian influenza virus, and has a good market application prospect.

The invention relates to a PCR (Polymerase Chain Reaction) kit and method for identifying brucella pathogens and application. The PCR kit comprises primer pairs and probes for simultaneously detecting brucella BA0711 vaccine strains, M5-9026 vaccine strains, Rev.1 vaccine strains and wild strains. A primer pair for detecting the brucella BA0711 vaccine strain is shown as SEQ ID NO.1-2, and a probe is shown as SEQ ID NO.3; a primer pair for detecting the M5-9026 vaccine strain is shown as SEQ ID NO.4-5, and a probe is shown as SEQ ID NO.6; a primer pair for detecting the Rev.1 vaccine strain is shown as SEQ ID NO.7-8, and a probe is shown as SEQ ID NO.9; a primer pair for detecting positive brucella is shown as SEQ ID NO.10-11, and a probe is shown as SEQ ID NO.12; the kit has the advantages of high sensitivity and strong specificity, and can simultaneously distinguish a plurality of vaccine strains and wild strains.

The invention provides a Brucella immunosuppressive gene BtpB deletion vaccine as well as a preparation method and application thereof, and belongs to the technical field of vaccine strains. The invention provides a suicide plasmid for knocking out a BtpB gene in a bovine brucella A19 vaccine strain and a gene deletion strain prepared on the basis of the suicide plasmid, and the BtpB gene deletion is performed on the brucella A19 strain so as to achieve the purpose of modifying the A19 vaccine. The A19 delta BtpB deletion strain constructed by the invention can reduce damage to host visceral organs, can induce a mouse to generate a high-titer Brucella specific antibody IgG, can better induce the mouse to generate Th1 type cytokines, and can provide better protective efficacy for the mouse than an A19 vaccine strain, so that the A19 delta BtpB deletion strain can be used as a vaccine for the mouse. The A19 delta BtpB deletion strain is expected to become a novel Brucella gene deletion vaccine candidate, and a theoretical basis and a data support are provided for developing a novel Brucella gene deletion vaccine.

The invention discloses a genetically engineered virus strain of an African swine fever virus, and in a genome of the genetically engineered virus strain, a D250R gene is an inactivated gene. The microbial preservation number of a parent strain for preparing the genetic engineering virus strain is CCTCC (China Center For Type Culture Collection) NO: V 202318, and the GenBank accession number of a genomic sequence of the strain is OQ504956.1. The invention also discloses a preparation method of the genetically engineered virus strain, a vaccine composition containing the genetically engineered virus strain, a preparation method of the vaccine composition, and application of the genetically engineered virus strain in preparation of a preparation for preventing African swine fever. The genetically engineered virus strain is good in safety and immune effectiveness, and has the potential of preparing clinically applied vaccines.

The invention relates to the technical field of molecular biological detection, and particularly discloses a quadruple fluorescent PCR primer probe combination, a reaction system and a detection method for identifying a mycoplasma gallisepticum wild strain and a vaccine strain. The quadruple fluorescent PCR primer probe combination for identifying the mycoplasma gallisepticum wild strain and the vaccine strain comprises a universal primer probe group for detecting mycoplasma gallisepticum and a specific primer probe group specially aiming at three vaccine strains F-36, TS-11 and 6 / 85 respectively. According to the quadruple fluorescent PCR primer probe combination, the reaction system and the method for identifying the mycoplasma gallisepticum wild strain and the vaccine strain, the purpose of simultaneously detecting and distinguishing DNA of the mycoplasma gallisepticum wild strain and DNA of three different vaccine strains (F-36, TS-11 and 6 / 85) of the mycoplasma gallisepticum wild strain can be achieved, so that detection and differential diagnosis are more efficient, economical, simple and convenient; the kit has the advantages of high sensitivity, good specificity, rapidness, high flux, simplicity and convenience in operation and the like.

The invention discloses a Newcastle disease vaccine strain with high antibody escape ability and a modification method thereof, the cell strain is preserved in China General Microbiological Culture Collection Center on January 19, 2024, the address of the preservation unit is CGMCC No.45870, No.1 yard, Beichen West Road, Chaoyang District, Beijing, and the classification name of the strain is Newcastle disease virus strain. The recombinant NDV vaccine strain has the same antigen site as the current NDV gene VII type epidemic strain and has the efficient proliferation efficiency superior to that of a classical vaccine strain La Sota, the thermal stability of the NDV vaccine strain is improved by the constructed recombinant vaccine strain, and the cost of vaccine cold-chain transportation is reduced.

The invention relates to a heat-resistant H1N1 subtype influenza virus mutant vaccine strain and application thereof. The invention belongs to the technical field of virus gene engineering, and particularly discloses a heat-resistant H1N1 subtype influenza virus mutant vaccine strain and application thereof. According to the H1N1 subtype influenza virus mutant vaccine strain and the preparation method thereof, the HA protein head region, which is a key region influencing the virus thermal stability, is mutated, the virus thermal stability can be remarkably improved only by mutating three amino acid sites, meanwhile, the virus still has good thermal stability after being inactivated, the H1N1 subtype influenza virus mutant vaccine strain prepared by HA protein point mutation has the preservation number of CCTCC NO: V202471, and the H1N1 subtype influenza virus mutant vaccine strain can be used for preparing the H1N1 subtype influenza virus mutant vaccine strain. And immune animals can be induced to generate high-level HI antibodies.

The invention belongs to but not limited to the technical field of genetic engineering technology, and discloses a construction method and application of a BspE gene deletion strain of Brucella effect protein, the BspE gene deletion strain is constructed by using homologous recombination and SacB reverse screening technology, Brucella abortus A19 vaccine strain liquid is used as a template, PCR amplification is carried out to obtain upstream and downstream homologous arms of BspE gene, and the BspE gene deletion strain is constructed by using the upstream and downstream homologous arms of the BspE gene. The method comprises the following steps: carrying out fusion PCR (Polymerase Chain Reaction) amplification on upstream and downstream homologous arms of a BspE gene subjected to gel recovery, and connecting and transforming an obtained fusion fragment and a pUC19-SacB plasmid to obtain a recombinant plasmid pUC19-delta BspE. The invention relates to a bovine brucella BspE deletion vaccine strain, which is characterized in that a plasmid is obtained, the plasmid is electrically transformed into a bovine brucella A19 competent cell, and the positive transformant is a bovine brucella BspE deletion strain through kanamycin resistance and sucrose pressure screening, PCR (polymerase chain reaction) identification and sequencing, and the deletion vaccine strain improves the levels of antibacterial cytokines and specific brucella antibody IgG, and can be used for preparing the bovine brucella BspE deletion vaccine strain. The Brucella attenuated vaccine strain is a novel Brucella candidate attenuated vaccine strain and has a good market prospect.

The invention provides a nucleic acid probe, a primer group, a kit, a detection method and application, and relates to the technical field of biology. The nucleotide sequence of the nucleic acid probe is as shown in SEQ ID NO. 1; wherein the 3'end of the nucleic acid probe is modified with MGB, and locked nucleic acid is modified at a base position corresponding to the difference between the swine fever wild strain and the swine fever vaccine strain in the nucleotide sequence. According to the nucleic acid probe, a specific sequence is utilized to precisely target a swine fever wild strain, and locked nucleic acid modification is introduced at a differential site, so that the recognition capability on single-base mismatch is remarkably enhanced, non-specific binding to a vaccine strain is thoroughly blocked, and false positive interference is eliminated; and 3 '-terminal MGB modification is matched to improve the binding stability and sensitivity, so that the efficient and accurate identification of the swine fever wild strain under the immune background is ensured.

The invention discloses a construction and identification method of an influenza B DNA vaccine, which comprises the following steps: step 1, downloading sequence information of an influenza B recommended strain B / Austria / 1359417 / 2021 in vaccine strain recommended components in 2022-2023, carrying out codon optimization on an HA gene of the strain, and then carrying out gene synthesis, and naming the gene as BHA; 2, highly conservative sequences of HA protein, M2e protein and NA protein are selected for series combination, gene synthesis is performed after codon optimization, and the gene is named as G3; 3, respectively extracting plasmid DNAs of the synthetic fragments for later use; 4, amplifying a target fragment by using a PCR technology so as to connect a carrier; and 5, carrying out a target gene and vector connection experiment. According to the present invention, the HA protein sequence of the DNA vaccine can be rapidly replaced by using the restriction enzyme cutting site, the preparation method is simple, the immunogenicity is good, the cross protection is good, the preparation cost is low, the preparation requirement of the large-scale influenza vaccine can be met, and the important scientific significance and the important social value are provided.

The invention provides a novel bovine nodular skin disease virus LSDV-125 strain and application thereof in vaccine preparation, and belongs to the technical field of virology. The problem that a novel vaccine strain which is clear in genetic background, stably weakened in virulence and capable of inducing broad-spectrum immune response is urgently needed is solved. The invention relates to a sheep pox virus strain, in particular to a sheep pox virus LSDV-125 which is named sheep pox virus LSDV-HLJ-2023, has the preservation number of CCTCC (China Center for Type Culture Collection) NO: V202537, and is preserved in China Center for Type Culture Collection on May 13, 2025. The method is mainly used for developing efficient and safe attenuated live vaccines.

The invention belongs to the technical field of virus detection, and discloses a digital PCR (polymerase chain reaction) kit for simultaneously detecting African swine fever virus, porcine reproductive and respiratory syndrome virus and swine fever virus, and the kit comprises primers and probes as shown in SEQ ID NO.1-SEQ ID NO.24. After a single system of an African swine fever virus-VP72 gene, an African swine fever virus-CD2V gene, an African swine fever virus-14L gene, a porcine reproductive and respiratory syndrome virus-RdRP gene, a porcine reproductive and respiratory syndrome virus-European strain, a porcine reproductive and respiratory syndrome virus-American strain, a swine fever virus-vaccine strain and a swine fever virus-wild strain is tested, a nine-fold digital PCR system containing an internal standard is established; through tests of indexes such as linearity, specificity, minimum detection limit, repeatability, comparison of a single digital PCR system and a multiple digital PCR system, the currently developed digital PCR multiple detection kit completely meets development requirements and is high in specificity and sensitivity, and the minimum detection limit of the digital PCR multiple detection kit can reach 10 Copies / mu L or below.

The invention relates to an efficient screening method and application of an influenza virus candidate vaccine strain, and the efficient screening method comprises the following steps: (1) diluting a mother generation influenza virus to be screened by using a virus maintenance solution, adding the diluted mother generation influenza virus into a culture plate containing canine kidney cells, adsorbing the canine kidney cells by the influenza virus, and discarding a virus solution in the culture plate; (2) covering the surfaces of the cells with a maintenance medium in a liquid state, cooling and solidifying the maintenance medium, and inversely placing the maintenance medium in an incubator to culture viruses; and (3) selecting virus spots, mixing the selected virus spots with a buffer solution, inoculating the obtained mixture into chick embryos and / or canine kidney cells, and culturing to obtain the candidate vaccine strain of the influenza virus. The method provided by the invention is simple and easy to operate, short in time consumption, low in cost, few in passage times and not easy to mutate, and can achieve the purpose of quickly and effectively screening out influenza virus vaccine candidate strains with excellent growth characteristics from mother generation virus seeds in a short time.

The invention belongs to the technical field of biological detection, and particularly relates to an SNP (Single Nucleotide Polymorphism) site for distinguishing a mycoplasma synoviae MS-H vaccine strain and a wild strain, a kit and application, and target genes meeting detection requirements are screened out by carrying out bioinformatics comparative analysis on whole genomes of MS-H and parent strains thereof. A specific primer and an MGB probe are designed for a specific conserved gene sequence ktrB gene for the first time, and the double qPCR kit for distinguishing the MS-H vaccine strain and the wild strain is established. In-vitro experiments prove that the kit disclosed by the invention is simple to operate, high in sensitivity, strong in specificity and good in repeatability. The screened gene loci and the established detection kit have the advantages that the defect that at present, common genes are prone to reverse mutation is overcome, the method can be used for clinical rapid diagnosis of MS vaccine strains and wild strains, the detection accuracy is improved, population purification is promoted, and certain commercial value is achieved.

A nanobody classical swine fever virus (CSFV)-E0-Nb1 against a CSFV E0 protein, and an encoding gene and use thereof are provided, belonging to the technical field of biological detection. The nanobody CSFV-E0-Nb1 has an amino acid sequence shown in SEQ ID NO: 1 and can be expressed using an expression system. The nanobody is coupled with a quantum dot to obtain an immunochromatographic test strip for distinguishing antibodies against a CSFV E2 subunit vaccine strain from those of a wild strain infected on site, and there is a simple production process of the test strip. The immunochromatographic test strip can differentiate and diagnose the antibodies against the CSFV E2 subunit vaccine strain and the wild strain, and has the advantages of rapid, convenient, and instant detection, thus providing a new method for the detection of classical swine fever (CSF) purification.

The invention discloses a construction method and application of a toxoplasma gondii polygene deletion vaccine strain. According to the invention, a TgBFD1 gene and a TgDAHPS gene are respectively knocked out from an ME49 [delta] 6pgdh1 insect strain through a gene editing technology, and a polygene deleted insect strain [delta] 6pgdh1 [delta] bfd1 [delta] dahps is successfully constructed; the strain can be subcultured in vitro, has the characteristics of no toxicity and no formation of tissue cysts in a host body, has better immune protection after immunization and inoculation, and can resist lethal infection of highly toxic strains. The toxoplasma gondii polygene deletion strain provided by the invention has better safety than ME49 delta 6pgdh1 strain, the toxicity of the toxoplasma gondii polygene deletion strain is obviously reduced, tissue cysts are not formed, the toxoplasma gondii polygene deletion strain can effectively resist infection of wild poisonous strains, the toxoplasma gondii polygene deletion strain has good immune protection capability, the defects that ME49 delta 6pgdh1 still has toxicity and can form tissue cysts are overcome, and the toxoplasma gondii polygene deletion strain has good application prospects. A method is provided for developing a safe and efficient toxoplasma gondii vaccine.

The invention discloses a dual fluorescent quantitative PCR (polymerase chain reaction) primer probe combination for identifying a PRV (pseudorabies virus) vaccine strain and a wild strain. The dual fluorescent quantitative PCR primer probe combination comprises two pairs of primers gB-F and gB-R, gE-F and gE-R, and probes gB-probe and gE-probe, wherein the two pairs of primers are used for specifically amplifying a PRV gB gene and a PRV gE gene; through existence of real-time fluorescence PCR amplification curves of the PRV gB gene and the gE gene, a PRV vaccine strain (gE gene deletion) and a wild strain can be rapidly, specifically, sensitively and stably identified, technical support can be provided for porcine pseudorabies epidemic disease monitoring, and thorough purification of the PRV in a live pig breeding link is facilitated.

This invention belongs to the field of biodetection technology, specifically relating to a monoclonal antibody combination for detecting the N protein of porcine reproductive and respiratory syndrome virus (PRRSV) and its application. The combination consists of monoclonal antibodies 1D7 and 5C7. Sequence analysis has clarified the CDR amino acid sequences of the heavy and light chain variable regions, as shown in SEQ ID NO.1-SEQ ID NO.12, and a double-antibody sandwich ELISA detection method has been established based on this. This method uses 1D7 as the coating antibody and 5C7 as the labeling antibody, achieving a sensitivity of up to 100 pg / mL, high specificity, no cross-reactivity with irrelevant antigens such as PEDV, and effectively detecting the N protein in PRRSV vaccine strains such as JXA1-R and R-98. This invention can be used for rapid detection of PRRSV antigen in clinical samples and for vaccine quality control.

The invention belongs to the field of biology, and discloses an mRNA (messenger ribonucleic acid) with a nucleotide sequence as shown in SEQ ID NO.3. Antiserum of a strain (A / chick / Gansuu / 28 / 2024) corresponding to the mRNA has relatively good reactivity with other strains and poorer reaction with a current vaccine strain RE-13, the branched strain is a current epidemic strain, and the mRNA prepared from the HA gene of the strain has the advantage of strong protection; the invention also aims to provide the mRNA, application thereof and a vaccine.

The invention relates to a primer-probe set, comprising a forward primer having the nucleotide sequence of SEQ ID NO:1 and a reverse primer having the nucleotide sequence of SEQ ID NO:2, and a peptide nucleic acid (PNA) probe having the sequence of HEX-OO-(SEQ ID NO:3)-Lysine-BHQ1, which are used for differentiating the Peste des Petits Ruminants (PPR) virus vaccine and field strains and for preventing false positive results arising from the PPR vaccine, as well as to their operating temperatures. Said primer-probe set can differentiate between the vaccine strain containing the nucleotide sequence of SEQ ID NO:4 and the field strain containing the nucleotide sequence of SEQ ID NO:5. Thus, by means of said primer-probe set, false positive results arising from the PPR vaccine are prevented, and accordingly, unnecessary quarantine measures are also avoided.

This invention discloses a candidate strain of *R. anatipestifer* double-gene deletion attenuated vaccine, its construction method, and its application. The candidate strain of *R. anatipestifer* double-gene deletion attenuated vaccine is *R. anatipestifer* strain CH-1. B739_RS01935-B739_RS07625 A candidate attenuated live vaccine strain with double gene deletion, deposited at the China Center for Type Culture Collection (CCTCC) on May 22, 2025, with accession number CCTCC NO: M20251080, at Wuhan University, Wuhan, China, has been deposited on that date. The attenuated live strain constructed in this invention showed no significant impact on the weight gain of ducklings after immunization, demonstrating good safety. Furthermore, the protection rate against challenge with the wild-type virulent RACH-1 strain reached 83.3% after immunization, indicating excellent immunoprotective efficacy.

The invention relates to the technical field of rotaviruses, in particular to a G8P [8] type group A rotavirus CZ-23 and application thereof. The invention relates to a G8P [8] type group A rotavirus CZ-23, which is preserved in China General Microbiological Culture Collection Center (CGMCC) on April 11, 2023, and the preservation address is No.3, Yard 1, Beichen West Road, Chaoyang District, Beijing; the preservation number is CGMCC (China General Microbiological Culture Collection Center) The invention provides a novel human rotavirus wild strain which is reported and separated for the first time in China, and the strain is strong in virus replication capability and good in hereditary stability, can be applied to development of vaccine strains of human rotavirus vaccines, and is suitable for attenuated rotavirus oral vaccines.

This invention relates to the field of molecular biology detection technology, specifically disclosing a quadruple fluorescent PCR primer-probe combination, reaction system, and detection method for identifying wild-type and vaccine strains of Mycoplasma gallisepticum. The quadruple fluorescent PCR primer-probe combination for identifying wild-type and vaccine strains of Mycoplasma gallisepticum includes a universal primer-probe set for detecting Mycoplasma gallisepticum and specific primer-probe sets targeting three vaccine strains, F-36, TS-11, and 6 / 85, respectively. The quadruple fluorescent PCR primer-probe combination, reaction system, and method of this invention for identifying wild-type and vaccine strains of Mycoplasma gallisepticum can simultaneously detect and differentiate the DNA of wild-type Mycoplasma gallisepticum and its three different vaccine strains (F-36, TS-11, and 6 / 85), making detection and differential diagnosis more efficient, economical, and convenient; it has advantages such as high sensitivity, good specificity, rapid high throughput, and simple operation.

The invention belongs to the technical field of animal epidemic disease pathogen detection, and particularly relates to a primer composition and a kit for identifying a Brucella universal type and a vaccine strain, the primer composition comprises primer pairs and probes for identifying the Brucella universal type, a pig breed S2 vaccine strain and a cattle breed A19 vaccine strain; the primer pair for identifying the universal type of Brucella is shown as SEQ ID NO.1-2, and the probe is shown as SEQ ID NO.3; a primer pair for identifying the pig breed S2 vaccine strain is SEQ ID NO.4-5, and a probe is SEQ ID NO.6; the primer pair for identifying the bovine species A19 vaccine strain is SEQ ID NO.7-8, and the probe is SEQ ID NO.9; the specificity and the sensitivity are good.